Effect of acetylsalicylic acid on thalassemia with pulmonary arterial hypertension

© 2014 Chueamuangphan et al. Objective: To compare pulmonary artery systolic pressure (PASP) between thalassemic patients with pulmonary arterial hypertension (PAH) for whom acetylsalicylic acid (ASA) was and was not prescribed after 1 year. Methods: A retrospective cohort study was conducted at the...

Full description

Saved in:
Bibliographic Details
Main Authors: Nonlawan Chueamuangphan, Wattana Wongtheptian, Jayanton Patumanond, Apichard Sukonthasarn, Suporn Chuncharunee, Chamaiporn Tawichasri, Weerasak Nawarawong
Format: Journal
Published: 2018
Subjects:
Online Access:https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84937542868&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/53705
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Chiang Mai University
id th-cmuir.6653943832-53705
record_format dspace
spelling th-cmuir.6653943832-537052018-09-04T09:56:12Z Effect of acetylsalicylic acid on thalassemia with pulmonary arterial hypertension Nonlawan Chueamuangphan Wattana Wongtheptian Jayanton Patumanond Apichard Sukonthasarn Suporn Chuncharunee Chamaiporn Tawichasri Weerasak Nawarawong Medicine © 2014 Chueamuangphan et al. Objective: To compare pulmonary artery systolic pressure (PASP) between thalassemic patients with pulmonary arterial hypertension (PAH) for whom acetylsalicylic acid (ASA) was and was not prescribed after 1 year. Methods: A retrospective cohort study was conducted at the hematological outpatient clinic at Chiang Rai Hospital, Chiang Rai, Thailand. All new cases of thalassemia with PAH from January 2007 to January 2012 were studied at the first month and at 12 months. The patients were classified into two groups. In one group, ASA 81 mg daily was prescribed for 1 year, whereas in another group no ASA was prescribed, due to its contraindications, which included bleeding, gastrointestinal side effects, and thrombocytopenia. PASP, estimated by a Doppler echocardiography, was measured by the same cardiologist. Propensity score adjustment was used to control confounding variables by indication and contraindication. Multivariable regression analysis was used to evaluate the effects of ASA.Results: Of the 63 thalassemia patients with PAH, there were 47 (74.6%) in the ASA group and 16 (25.4%) in the no ASA group. ASA, as compared with no ASA, did not significantly reduce PASP (adjusted difference -0.95; 95% confidence interval -16.99 to 15.10; P=0.906). Conclusion: Low-dose ASA may not have a beneficial effect on PASP after 1 year of treatment of PAH in thalassemia. 2018-09-04T09:56:12Z 2018-09-04T09:56:12Z 2014-12-03 Journal 11787074 2-s2.0-84937542868 10.2147/IJGM.S71644 https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84937542868&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/53705
institution Chiang Mai University
building Chiang Mai University Library
country Thailand
collection CMU Intellectual Repository
topic Medicine
spellingShingle Medicine
Nonlawan Chueamuangphan
Wattana Wongtheptian
Jayanton Patumanond
Apichard Sukonthasarn
Suporn Chuncharunee
Chamaiporn Tawichasri
Weerasak Nawarawong
Effect of acetylsalicylic acid on thalassemia with pulmonary arterial hypertension
description © 2014 Chueamuangphan et al. Objective: To compare pulmonary artery systolic pressure (PASP) between thalassemic patients with pulmonary arterial hypertension (PAH) for whom acetylsalicylic acid (ASA) was and was not prescribed after 1 year. Methods: A retrospective cohort study was conducted at the hematological outpatient clinic at Chiang Rai Hospital, Chiang Rai, Thailand. All new cases of thalassemia with PAH from January 2007 to January 2012 were studied at the first month and at 12 months. The patients were classified into two groups. In one group, ASA 81 mg daily was prescribed for 1 year, whereas in another group no ASA was prescribed, due to its contraindications, which included bleeding, gastrointestinal side effects, and thrombocytopenia. PASP, estimated by a Doppler echocardiography, was measured by the same cardiologist. Propensity score adjustment was used to control confounding variables by indication and contraindication. Multivariable regression analysis was used to evaluate the effects of ASA.Results: Of the 63 thalassemia patients with PAH, there were 47 (74.6%) in the ASA group and 16 (25.4%) in the no ASA group. ASA, as compared with no ASA, did not significantly reduce PASP (adjusted difference -0.95; 95% confidence interval -16.99 to 15.10; P=0.906). Conclusion: Low-dose ASA may not have a beneficial effect on PASP after 1 year of treatment of PAH in thalassemia.
format Journal
author Nonlawan Chueamuangphan
Wattana Wongtheptian
Jayanton Patumanond
Apichard Sukonthasarn
Suporn Chuncharunee
Chamaiporn Tawichasri
Weerasak Nawarawong
author_facet Nonlawan Chueamuangphan
Wattana Wongtheptian
Jayanton Patumanond
Apichard Sukonthasarn
Suporn Chuncharunee
Chamaiporn Tawichasri
Weerasak Nawarawong
author_sort Nonlawan Chueamuangphan
title Effect of acetylsalicylic acid on thalassemia with pulmonary arterial hypertension
title_short Effect of acetylsalicylic acid on thalassemia with pulmonary arterial hypertension
title_full Effect of acetylsalicylic acid on thalassemia with pulmonary arterial hypertension
title_fullStr Effect of acetylsalicylic acid on thalassemia with pulmonary arterial hypertension
title_full_unstemmed Effect of acetylsalicylic acid on thalassemia with pulmonary arterial hypertension
title_sort effect of acetylsalicylic acid on thalassemia with pulmonary arterial hypertension
publishDate 2018
url https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84937542868&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/53705
_version_ 1681424184964546560